Hypertrophic Cardiomyopathy - Pipeline Review, H1 2020

April 2020 | 88 pages | ID: H82E53EE2CCEN
Global Markets Direct

Abstracts

Hypertrophic Cardiomyopathy - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertrophic Cardiomyopathy - Pipeline Review, H1 2020, provides an overview of the Hypertrophic Cardiomyopathy (Cardiovascular) pipeline landscape.

Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise, sensation of rapid, fluttering or pounding heartbeats and heart murmur. Hypertrophic cardiomyopathy usually is inherited. Treatment includes beta blockers, calcium channel blockers and blood thinners.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertrophic Cardiomyopathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hypertrophic Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Hypertrophic Cardiomyopathy - Overview
Hypertrophic Cardiomyopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hypertrophic Cardiomyopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypertrophic Cardiomyopathy - Companies Involved in Therapeutics Development
Algomedix Inc
C&C BioPharma LLC
Celltrion Inc
Cytokinetics Inc
Lead Discovery Center GmbH
MyoKardia Inc
Novartis AG
Toa Eiyo Ltd
Hypertrophic Cardiomyopathy - Drug Profiles
(sacubitril + valsartan) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
8-MI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CK-274 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTG-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit PDE3A1 for Hypertrophic Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HCM-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mavacamten - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MYK-224 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MYK-581 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides to Agonize MFN2 for Charcot Marie Tooth Disease Type IIA and Hypertrophic Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Cardiac Hypertrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPC6 for Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, Hypertrophy Cardiomyopathy and Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit GRK5 for Type 2 Diabetes and Cardiac Hypertrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TY-0305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypertrophic Cardiomyopathy - Dormant Projects
Hypertrophic Cardiomyopathy - Product Development Milestones
Featured News & Press Releases
Mar 30, 2020: MyoKardia announces Mavacamten treatment well tolerated and significantly reduced biomarkers of cardiac injury and wall stress in non-obstructive hypertrophic cardiomyopathy patients
Mar 26, 2020: MyoKardia provides clinical trial update on Mavacamten
Mar 26, 2020: MyoKardia provides clinical trial update in the context of the COVID-19 pandemic
Feb 20, 2020: Cytokinetics announces preclinical data for CK-3773274 presented at the Biophysical Society 64th Annual Meeting
Jan 06, 2020: Cytokinetics announces Start of Redwood-HCM, a phase 2 clinical trial of CK-3773274
Nov 11, 2019: MyoKardia announces 48-week data from PIONEER-OLE study of Mavacamten
Nov 11, 2019: MyoKardia announces positive topline data from its phase 2 MAVERICK-HCM clinical trial of mavacamten
Nov 04, 2019: MyoKardia announces abstracts on mavacamten selected for presentation at the American Heart Association Scientific Sessions 2019
Sep 16, 2019: Cytokinetics announces data from phase 1 study of CK-3773274 at the HFSA 23 Annual Scientific Meeting
Sep 10, 2019: MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients
Sep 06, 2019: Cytokinetics to present on its Hypertrophic Cardiomyopathy drug candidate CK-274 at 23rd Annual HFSA Scientific Meeting
Aug 31, 2019: MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019
Aug 26, 2019: MyoKardia announces mavacamten abstract selected for presentation at the European Society of Cardiology Congress 2019
Aug 26, 2019: MyoKardia announces MYK-581 abstract selected for presentation at the European Society of Cardiology Congress 2019
Aug 23, 2019: MyoKardia starts dosing hypertrophic cardiomyopathy patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hypertrophic Cardiomyopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hypertrophic Cardiomyopathy - Pipeline by Algomedix Inc, H1 2020
Hypertrophic Cardiomyopathy - Pipeline by C&C BioPharma LLC, H1 2020
Hypertrophic Cardiomyopathy - Pipeline by Celltrion Inc, H1 2020
Hypertrophic Cardiomyopathy - Pipeline by Cytokinetics Inc, H1 2020
Hypertrophic Cardiomyopathy - Pipeline by Lead Discovery Center GmbH, H1 2020
Hypertrophic Cardiomyopathy - Pipeline by MyoKardia Inc, H1 2020
Hypertrophic Cardiomyopathy - Pipeline by Novartis AG, H1 2020
Hypertrophic Cardiomyopathy - Pipeline by Toa Eiyo Ltd, H1 2020
Hypertrophic Cardiomyopathy - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hypertrophic Cardiomyopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Algomedix Inc
C&C BioPharma LLC
Celltrion Inc
Cytokinetics Inc
Lead Discovery Center GmbH
MyoKardia Inc
Novartis AG
Toa Eiyo Ltd